Clinical trialPhase 1Unknown
Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors
First-in-human (FIH), Open-Label, Phase 1a (Dose Escalation)/Phase 1b (Expansion Cohort) Trial of BJ-001 as a Single Agent and in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Solid Tumors
- Outcome
- Outcome unknown
- Phase
- Phase 1
- Status
- Unknown
- Study type
- Interventional
- Start
- 4 December 2019
- Listed end
- 22 October 2024
- Enrollment
- 92 participants
- Sites
- 5
- Primary outcomes
- Frequency of adverse events (AEs) and SAE; Severity of AEs in patients with solid tumors enrolled in the study.; Dose limiting toxicities (DLTs) BJ-001 as a single agent; Dose limiting toxicities (DLTs) BJ-001 in combination with pembrolizumab inhibitor.
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 9 November 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to assess the safety and tolerability of BJ-001, a human IL-15 fusion protein, administered via subcutaneous injections, as a single agent and in combination with pembrolizumab in adult patients with Locally Advanced/Metastatic Solid Tumors